Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juan Arévalo-Serrano has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of frailty in patients with advanced chronic kidney disease, and the role of microvesicles: A single-center study

    by Rocio Gimena Muñoz, Gemma Valera Arévalo, María del Mar Rodríguez San Pedro, María Pérez Fernández, Juan Arévalo Serrano, Sushrut S. Waikar, Rafael Ramírez-Chamond, Diego Rodríguez Puyol, Julia Carracedo, Patricia Martinez Miguel

    Background: Frailty is a highly prevalent syndrome in patients with advanced age and chronic diseases, and it is associated with atherothrombotic pathologies, suggesting a procoagulant state in these patients. Circulating microvesicles (cMVs), are small phospholipid-rich vesicles, which have been shown to participate in atherothrombotic onset and progression. We aim to analyze frailty in patients with advanced chronic kidney disease (CKD), and to determine the role of microvesicles in this population. Materials and methods: We conducted a prospective cohort study with 85 patients with advanced CKD. Our main objective was to evaluate frailty and its novel association with circulating microvesicles in advanced CKD. To define frailty, Fried’s five criteria were used and we obtained blood for cMVs analysis by flow cytometry. Results: The prevalence of frailty in patients with advanced CKD was 27% (CI 95% 17-37%). We found that risk factors for frailty were age (OR 1.06; CI 95% to 1.11; p=0.027), type 2 diabetes mellitus (OR 5.77; CI 95% to 18.9; p=0.004) and hemoglobin (g/dL) (OR 0.63; CI 95% to 0.94; p=0.023). Total cMVs, platelet derived cMVs and endothelial derived cMVs were significantly higher in frail patients. In the predictive multivariable binary logistic regression model over frailty, three predictors explain 41% of the variability of frailty (Nagelkerke square R = 0.41; p <0.001) with the following contribution: T2DM (19%), total cMVs (14%) and hemoglobin (8%). Discussion: Frailty is highly prevalent in patients with advanced CKD. Although we still do not know in depth the mechanisms involved in frailty, to our knowledge this is the first study that links cMVs and frailty in patients with advanced CKD. In our opinion it could be explored as a good biomarker or therapeutic target in advanced CKD.

  • Open Access

    Evaluation of the management of Clostridioides difficile infection as a risk factor for recurrence. A retrospective observational study

    by José Mª Barbero Allende, Iván Ureña, Leticia Cañivano, Sara García, Cristina Paz, Álvaro Olmo-Ruiloba, Koldo Jauregi, Sandra Coronado, Lucas López Requejo, Laura Porcel, et al.

    Introduction. One of the main problems with Clostridioides difficile infection (CDI) is its tendency to recur. The objective of the study is to analyze which factors in the clinical management of CDI favor recurrence. Material and methods. This is a retrospective study conducted at the Hospital Universitario Príncipe de Asturias on cases of CDI between January 2021 and June 2023. Demographic variables, comorbidities, risk factors for recurrence, and treatments used for CDI were recorded. Non-optimal clinical management was defined as: not discontinuing treatment with proton pump inhibitors (PPIs) if the patient was on them, not discontinuing concomitant antibiotic treatments if the patient was on these, the use of metronidazole monotherapy in any case, or the use of standard-dose vancomycin if there were risk factors for recurrence. Results. A total of 327 cases were found in 256 patients. 69 patients died within 8 weeks after the episode (26.9%). Among the remaining 258 episodes, there were 68 recurrences (26.3%). Of these 68 recurrences, 63 cases received nonoptimal treatment (93.2%), compared to 112/190 (58.9%) among those who did not recur. In the multivariate analysis adjusted for confounding factors, patients who received optimal treatment had an 89% lower risk of recurrence compared to those who did not receive it (OR 0.1; p < 0.001). Conclusions. Reducing the use of PPIs and antibiotics and prioritizing more effective treatments against CDI could improve the recurrence rates of this infection.

  • Open Access

    Grief and coping among relatives of patients who died of COVID-19 in intensive care during the height of the COVID-19 pandemic

    by Sancho Rodriguez-Villar, Elijah Oluwafemi Okegbola, Juan Arevalo-Serrano, Yasmine Duval, Annie Mathew, Carmen Rodriguez-Villar, Kirsten V. Smith, Robert Charles Kennedy, Holly G. Prigerson

    Background: The grief of relatives of patients who died of COVID-19 in an intensive care unit (ICU) has exacted an enormous toll worldwide. Aims: To determine the prevalence of probable prolonged grief disorder (PGD) at 12 months post-loss and beyond. We also sought to examine circumstances of the death during the COVID-19 pandemic that might pose a heightened risk of PGD, and the associations between probable PGD diagnosis, quality of life and social disconnection. Method: We conducted an observational, cross-sectional multicentre study of the next of kin of those who died of COVID-19 between March 2020 and December 2021. Participants were recruited from ICUs in South-East London. The Prolonged Grief Disorder Scale (PG-13-R), Quality-of-Life Scale (QOLS) and Oxford Grief-Social Disconnection Scale (OG-SD) were used. Results: A total of 73 relatives were recruited and assessed, all of them over a year after their loss. Twenty-five (34.2%; 95% CI 23.1–45.4%) relatives of patients who died in the ICU met the criteria for PGD. Those who met the criteria had significantly worse quality of life (QOLS score mean difference 26; 95% CI 17–34; P < 0.001) and endorsed greater social disconnection (OG-SD score means difference 41; 95% CI 27–54; P < 0.001). Conclusions: The findings suggest that rates of PGD are elevated among relatives of patients who died of COVID-19 in the ICU. This, coupled with worse quality of life and greater social disconnection experienced by those meeting the criteria, suggests the need to attend to the social deprivations and social dysfunctions of this population group.


  • Open Access

    Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients

    by Jorge Monserrat, Ana Gómez-Lahoz, Miguel A. Ortega, José Sanz, Benjamin Muñoz, Juan Arévalo-Serrano, José Miguel Rodríguez, Jose Maria Gasalla, Óscar Gasulla, Alberto Arranz, et al.

    SARS-CoV-2 is a new coronavirus characterized by a high infection and transmission capacity. A significant number of patients develop inadequate immune responses that produce massive releases of cytokines that compromise their survival. Soluble factors are clinically and pathologically relevant in COVID-19 survival but remain only partially characterized. The objective of this work was to simultaneously study 62 circulating soluble factors, including innate and adaptive cytokines and their soluble receptors, chemokines and growth and wound-healing/repair factors, in severe COVID-19 patients who survived compared to those with fatal outcomes. Serum samples were obtained from 286 COVID-19 patients and 40 healthy controls. The 62 circulating soluble factors were quantified using a Luminex Milliplex assay. Results. The patients who survived had decreased levels of the following 30 soluble factors of the 62 studied compared to those with fatal outcomes, therefore, these decreases were observed for cytokines and receptors predominantly produced by the innate immune system—IL-1α, IL-1α, IL-18, IL-15, IL-12p40, IL-6, IL-27, IL-1Ra, IL-1RI, IL-1RII, TNFα, TGFα, IL-10, sRAGE, sTNF-RI and sTNF-RII—for the chemokines IL-8, IP-10, MCP-1, MCP-3, MIG and fractalkine; for the growth factors M-CSF and the soluble receptor sIL2Ra; for the cytokines involved in the adaptive immune system IFNγ, IL-17 and sIL-4R; and for the wound-repair factor FGF2. On the other hand, the patients who survived had elevated levels of the soluble factors TNFβ, sCD40L, MDC, RANTES, G-CSF, GM-CSF, EGF, PDGFAA and PDGFABBB compared to those who died. Conclusions. Increases in the circulating levels of the sCD40L cytokine; MDC and RANTES chemokines; the G-CSF and GM-CSF growth factors, EGF, PDGFAA and PDGFABBB; and tissue-repair factors are strongly associated with survival. By contrast, large increases in IL-15, IL-6, IL-18, IL-27 and IL-10; the sIL-1RI, sIL1RII and sTNF-RII receptors; the MCP3, IL-8, MIG and IP-10 chemokines; the M-CSF and sIL-2Ra growth factors; and the wound-healing factor FGF2 favor fatal outcomes of the disease.


  • Open Access

    Impact of the Innate Inflammatory Response on ICU Admission and Death in Hospitalized Patients with COVID-19

    by Jorge Monserrat, Angel Asunsolo, Ana Gómez-Lahoz, Miguel A. Ortega, Jose Maria Gasalla, Óscar Gasulla, Jordi Fortuny-Profitós, Ferran A. Mazaira-Font, Miguel Teixidó Román, Alberto Arranz, et al.

    Objective: To describe the capacity of a broad spectrum of cytokines and growth factors to predict ICU admission and/or death in patients with severe COVID-19. Design: An observational, analytical, retrospective cohort study with longitudinal follow-up. Setting: Hospital Universitario Príncipe de Asturias (HUPA). Participants: 287 patients diagnosed with COVID-19 admitted to our hospital from 24 March to 8 May 2020, followed until 31 August 2020. Main outcome measures: Profiles of immune response (IR) mediators were determined using the Luminex Multiplex technique in hospitalized patients within six days of admission by examining serum levels of 62 soluble molecules classified into the three groups: adaptive IR-related cytokines (n = 19), innate inflammatory IR-related cytokines (n = 27), and growth factors (n = 16). Results: A statistically robust link with ICU admission and/or death was detected for increased serum levels of interleukin (IL)-6, IL-15, soluble (s) RAGE, IP10, MCP3, sIL1RII, IL-8, GCSF and MCSF and IL-10. The greatest prognostic value was observed for the marker combination IL-10, IL-6 and GCSF. Conclusions: When severe COVID-19 progresses to ICU admission and/or death there is a marked increase in serum levels of several cytokines and chemokines, mainly related to the patient’s inflammatory IR. Serum levels of IL-10, IL-6 and GCSF were most prognostic of the outcome measure.


  • Open Access

    Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn’s Disease: A Retrospective Cohort Study

    by Yago González-Lama, Cristina Suárez, Irene González-Partida, Marta Calvo, Virginia Matallana, Juan de la Revilla, Marta Magaz, Cristina Bernardo, Belén Agudo, Pilar Ibarrola, et al.

    Introduction: Early stages of Crohn’s disease [CD] are predominantly inflammatory and early treatment could be useful to change the natural history of CD. We aimed to evaluate the impact of early treatment in our cohort of CD patients. Methods: We retrospectively reviewed clinical records of all CD patients at our centre who have received immunomodulators. Time from diagnosis to first CD-related major abdominal surgery or end of follow-up was considered. Dates of diagnosis, of starting immunomodulators (thiopurines / anti-tumour necrosis factor [TNF]), and of the first CD-related surgery when appropriate were collected. Results: Of 422 patients who received thiopurines, 189 operated patients started thiopurines after a median of 117 months (interquartile range [IQR] 44–196) since diagnosis; non-operated patients, after a median of 30 months [IQR 6–128], p < 0,005. Odds ratio [OR] for surgery was 1.006 (95% confidence interval [CI]1.004–1008) for each month of delay in starting thiopurines. Among 272 patients who received anti-TNFs, 137 operated patients started anti-TNFs after a median of 166 months [IQR 90–233] since diagnosis; non-operated patients after a median of 59 months [IQR 14–162]; p < 0,005. OR for surgery was 1.008 [95% CI 1.005–1.010] for each month of delay in starting anti-TNFs. Among 467 patients who received thiopurines and/or anti-TNF, 210 operated patients started any immunomodulator after a median of 120 months [IQR 48–197] since diagnosis and non-operated patients after a median of 30 months [IQR 6–126], p < 0,005. OR for surgery was 1.008 [95% CI 1.005–1.010] for each month of delay in starting immunomodulators. Conclusions: In our experience, time between diagnosis and thiopurine or anti-TNF initiation was associated with the risk of major abdominal surgery in Crohn’s disease.


  • Correlation between structural and functional damage in three different types of open angle glaucoma

    by M Castejon, G Bolivar, E Arranz‐Marquez, J Arevalo‐Serrano, Ma Teus

    Purpose To analyze the correlation between Optic Nerve Head (ONH) parameters, evaluated using Optical Coherence Tomography (OCT), and visual field damage in newly diagnosed patients with Pseudo Exfoliative Glaucoma (PEXG), Focal Damage Glaucoma (FG) and Hyperbaric Glaucoma (HG). Methods This is a prospective, cross sectional study. Basal, untreated IOP was recorded in all subjects. When both eyes of the same subject fulfilled the inclusion criteria, only one eye was randomly chosen for analysis. OCT stratus 3.0, fast optic disc strategy and Humphrey conventional achromatic perimetry (sita 24‐2) were performed. Linear regression analyses and Pearson’s correlation coefficients between several ONH parameters and the global Visual Field (VF) indices were used for the statistical analysis. Results 36 HB, 43 FG and 28 PEXG eyes were included in the study. We found strong and statistically significant correlations between the MD and the majority of the structural parameters of the ONH in the HB and PEXG groups. No significant correlation was found between any ONH parameter and MD in the FG group. We also found statistically significant correlations between most ONH parameters and the PSD in HB PEXG and FG groups. Conclusion The correlation between morphological visual field damage is different in different type of Open Angle Glaucomas.